Depends when they started the conversation and how competitive potential partners are for securing this “First in class” drug. TO confirmed conversation has been on going for years. The questions posed for phase 2 extension studies which were answered may have come through our advisory board. Look at who they connected to, may offer some idea who is the 3 from top 20 big phama’s taking interest at the moment…..or might not
Scientific due diligence is obviously advanced and has been ongoing. Financial due diligence would run parallel and then there after.
I do agree 1 month very unlikely. 10 weeks maybe. Allowing a few board meeting cycles. Near term has been stated multiple times but this is biotechnology and near term can be at snails pace.
(20min delay)